High-risk neuroblastoma cases with TERT oncogene rearrangement

Neuroblastoma is the most common solid tumour in early childhood and accounts for 15% of all childhood cancer death. Approximately a quarter of high-risk neuroblastoma is caused by TERT oncogene rearrangement.

Children with this subtype of neuroblastoma have less than 40% survival rate and are typically treated with surgery and toxic chemotherapy, meaning those that do survive often suffer life-long side effects.The funding from Neuroblastoma Australia will allow our team at Children’s Cancer Institute to identify the specific drivers of TERT oncogene rearrangement in high-risk neuroblastoma and demonstrate novel therapies that specifically target these drivers. Dr Tao LiuWe hope that, if successful, these novel therapies can be taken into clinical trials to see the first targeted therapy for patients with neuroblastoma due to TERT oncogene rearrangement, leading to better survival rates and better quality of life for children with this devastating childhood cancer.

This research will be undertaken by Associate Professor Tao Liu at the Children’s Cancer Institute. Watch his video update below. 

Photo of Associate Professor Tao Liu



 

 

More information